Checkmate Pharmaceuticals Inc

NASDAQ:CMPI  
12.73
-0.02 (-0.16%)
Earnings Announcements

Checkmate Pharmaceuticals Reports Third Quarter 2020 Financial Results And Provides An Update On Recent Progress

Published: 11/13/2020 12:15 GMT
(CMPI) - Checkmate Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides an Update on Recent Progress.
Checkmate Pharmaceuticals Inc Qtrly Net Loss $9.8mln.
Checkmate Pharmaceuticals Inc - Remains on Track to Initiate 3 Phase 2 Trials Combining Cmp-001 With Pd-1 Blockade by Late 2020/early 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.48

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.71

More details on our Analysts Page.